^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SL-279252
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shattuck
Drug class:
PD1 inhibitor, OX40 agonist
Related drugs:
Phase 1
Shattuck Labs, Inc.
Completed
Last update posted :
06/12/2024
Initiation :
03/26/2019
Primary completion :
05/04/2023
Completion :
05/04/2023
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK fusion
|
SL-279252
Share
